ClinicalTrials.gg
RecruitingNCT06445322Updated Oct 9, 2026

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

An observational study in Stargardt Disease, Stargardt Disease 1 and Cone Rod Dystrophy, sponsored by Ascidian Therapeutics, Inc. Recruiting at 9 sites in United States. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Ascidian Therapeutics, Inc · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Oct 9, 2026Site recruiting status changedStudy contact changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
50
Ages
5 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.

Planned enrollment
9th of 16
50 · median 63
Started
2024
with 5 others
Observational
16 of 42
8 open now
Primary completion
2027-08
later than 8 of 24 live
Registered
31st of 42
by date
Lead sponsor
2 of 42
Ascidian Therapeutics, Inc

Among the 42 studies in Stargardt Disease with a site in United States, this one is the 9th largest by planned enrollment of the 16 observational ones that give a count, is one of 6 that started in 2024, is one of 16 observational ones, reaches primary completion later than 8 of the 24 other live ones, and was the 31st registered.

Stargardt Disease

68 studies on the registry are indexed under Stargardt Disease; 27 are open to participants now.

Browse Stargardt Disease studies →

Open to participants now

16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Stargardt Disease studies recruiting now, 15 (63%) set no upper age limit and 7 (29%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 5 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Stargardt Disease with a site in United States, or all of them as a file.
02

Study summary

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.

Read the detailed description

The prescreening process will be used to help determine the initial eligibility and interest of potential participants in ACDN-01 clinical trials by conducting assessments of key eligibility criteria before the clinical trial screening procedures are performed.

03

Conditions studied

  • Stargardt Disease
  • Stargardt Disease 1
  • Cone Rod Dystrophy
  • Juvenile Macular Degeneration

Keywords

  • ABCA4
  • ABCA4-related retinopathy
  • Stargardt Disease
  • Stargardt macular dystrophy
  • Cone rod dystrophy
  • Gene editing
  • RNA
  • Gene Therapy
  • Exon editing
  • IRD
  • Inherited retinal disease
  • Inherited retinal dystrophy
  • Inherited retinal degeneration
04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Males and females with a diagnosis of ABCA4-related retinopathy will be invited to give informed consent prior to prescreening procedures. After appropriate informed consent/assent has been obtained, potential participants will then undergo the assessments to determine eligibility for ACDN-01 clinical trials.

Eligibility criteria

Key Inclusion Criteria:

  • Presence of mutations in the ABCA4 gene
  • ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy)

Key Exclusion Criteria:

  • The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy
  • Retinal disease other than ABCA4-related retinopathy
  • Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prescreening Group

    The prescreening study consists of genetic and visual assessments and will require at least 1 onsite visit. All clinical assessments performed are for the purpose of determining research eligibility for ACDN-01 clinical trials.

    Diagnostic Test: Prescreening Assessments

Interventions

  • Diagnostic testPrescreening Assessments

    Various genetic and visual assessments.

06

What researchers measure

Primary outcomes

  1. Confirm mutations in the ABCA4 gene

    Using a Clinical Laboratory Improved Amendments (CLIA)-certified laboratory.

    Time frame: 12 months

  2. Confirm the absence of pathogenic mutations in genes known to cause retinal disease other than ABCA4-related retinopathy

    Using a Clinical Laboratory Improved Amendments (CLIA)-certified laboratory.

    Time frame: 12 months

  3. Measure BCVA and LLVA

    Measure best corrected visual acuity and low luminance visual acuity

    Time frame: 12 months

  4. Measure the area of retinal atrophy

    Using FAF imaging

    Time frame: 12 months

  5. Measure baseline retinal structure

    Using OCT (SD-OCT)

    Time frame: 12 months

  6. Historical FAF or OCT images

    Confirm historical timepoint images

    Time frame: 4 years

  7. Historical BCVA/LLVA measurements

    Collect past measurements

    Time frame: 4 years

07

Study locations

7 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Aug 2027, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2024
First posted
Jun 6, 2024
StartActual
Jun 20, 2024
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2030
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 2 sites changed recruiting status (2 now terminated)
Show 2 sites
  • University of San Francisco · San Francisco, United StatesRecruiting→Terminated
  • Wilmer Eye Institute at John Hopkins · Baltimore, United StatesRecruiting→Terminated
Show site
  • Boston Children's Hospital · Boston, United States
Oct 9, 2026
Contact
Study contact changed: r•••@ascidian-tx.com · •••0412→r•••@ascidian-tx.com · •••0412. See the current contact
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    1 site added. 2 sites changed recruiting status (2 now terminated)
    Show 2 sites
    • University of San Francisco · San Francisco, United StatesRecruiting→Terminated
    • Wilmer Eye Institute at John Hopkins · Baltimore, United StatesRecruiting→Terminated
    Show site
    • Boston Children's Hospital · Boston, United States
    Contact Study contact changed: r•••@ascidian-tx.com · •••0412→r•••@ascidian-tx.com · •••0412. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06445322
Lead sponsor
Ascidian Therapeutics, Inc
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Jun 20, 2024
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2030 (estimated)
Last update
Oct 9, 2026

Study contacts

Senior Clinical Trial Manager
Contact
researchtrials@ascidian-tx.com
207-573-0412
Murray Abramson, MD, PhD
study director · Ascidian Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion